The Pipeline

Home>News>The Pipeline

Cartherics to present and exhibit at Emergence 2024

Cartherics is pleased to announce that it will be attending Emergence 2024 – The Era of Abundance investment conference at the Hilton Sydney next week.

The company’s CEO, Prof. Alan Trounson AO, will be presenting at 11:14 am on Wednesday 28th February. His presentation will discuss:

  • Cartherics’ breakthrough approach to treating solid tumours.
  • How CTH-401, […]
2024-02-22T15:57:01+11:00February 22nd, 2024|

Cartherics’ CEO discusses the future of solid tumour therapy

Cartherics’ CEO, Prof. Alan Trounson AO was recently interviewed by Wholesale Investor to discuss the company’s latest developments and the future of solid tumour therapy. In the interview Alan, shares insights into Cartherics’ cutting-edge technology, including the use of gene-edited natural killer (NK) cells and the strategic approach to leveraging a robust IP portfolio for […]

2024-02-15T15:18:52+11:00February 15th, 2024|

Ovarian cancer: Biotech company Cartherics to start human trials of new drug

There’s an urgent need for new treatment options for ovarian cancer patients who are often diagnosed at advanced stages when survival outcomes are worse. Cartherics’ lead cell therapy CTH-401 is a natural killer (NK) cell product designed to seek out and destroy the cells that cause ovarian cancer, with clinical trials planned for early next […]

2024-02-12T15:37:35+11:00February 12th, 2024|

Positive pre-IND meeting with US FDA for new ovarian cancer cell therapy

Melbourne, Australia, 1 February 2024 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, is pleased to announce that it has successfully completed a pre-investigational new drug (pre-IND) meeting with the US Food and Drug Administration (FDA) for a Phase I/II clinical trial of its […]

2024-02-01T15:38:56+11:00February 1st, 2024|

Chimeric Antigen Receptor (CAR) – Natural Killer (NK) Cells – Looking good for cancer therapy

As published in Drug Target Review

 Professor Alan Trounson, AO

Dr Huimin Cao

Dr Aleta Pupovac

The suitability of NK cells for cancer therapy has been challenged by some investor and business interests because of limited efficacy data from clinical trials, but is this really a valid belief at the present stage of development of the immune therapy […]

2023-11-28T15:36:13+11:00November 28th, 2023|

Rearming the body to fight cancer

Cartherics is currently undertaking a new capital raise to initiate clinical trials for its lead allogeneic cell therapy for ovarian cancer. CTH-401 is the only NK cell product currently under development that targets the adenocarcinoma specific antigen – TAG-72.

The company is looking to raise up to AU$20 million to support its ongoing development activities and […]

2023-11-15T16:28:45+11:00November 15th, 2023|

Importance of building Australia-China biotech collaborations

China is Australia’s greatest two-way trading partner in products and services, making up close to one-third of the nation’s international trade, as per the Australian Department of Foreign Affairs and Commerce. Resources and energy make up the largest share of Australia’s exports to China, with iron ore, natural gas and gold leading the way.

There are a number […]

2023-11-01T13:46:01+11:00November 1st, 2023|

Life Science Success podcast with Prof. Alan Trounson

Cartherics’ CEO, Prof. Alan Trounson, was recently a guest on Life Science Success podcast. Hosted by Dr Don Davies, this episode of the podcast discusses the future of cancer treatment and the importance of developing more precise and accessible treatment alternatives for patients with solid cancers.

Key discussion points from the podcast:

  • Alan Trounson has a […]
2023-10-20T09:42:22+11:00October 20th, 2023|

Cartherics appoints new Chief Scientific Officer

Melbourne, Australia, 17 October 2023 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for the treatment of cancer, announced today that it has appointed Dr Walid Azar as Chief Scientific Officer (CSO), effective immediately. He holds extensive experience from a diverse scientific background encompassing both academic research and […]

2023-10-17T20:06:39+11:00October 17th, 2023|

Ovarian cancer is not ovarian cancer

Cartherics’ Dr Ian Nisbet (Chief Operating Officer) and Kathy Skoff (Clinical Trials Manager) recently attended an ovarian cancer symposium in Sydney, organised by Ovarian Cancer Australia and sponsored by AstraZeneca and GSK.  It was an excellent event, with an exceptional panel of speakers who provided overviews of the different types of ovarian cancer along with […]

2023-10-03T12:56:36+11:00October 3rd, 2023|
Go to Top